For instance, the glycosylated spirotetronate tetrocarcin A has emerged as a promising candidate for future evaluation in cancer therapy due to its ability to downregulate the expression of the tight junction protein Junctional Adhesion Molecule-A (JAM-A), attenuate tumorigenic signaling, and induce apoptosis [10]. The gene discussed is F11R; the disease is cancer.